Gain Therapeutics reported financial results for the second quarter ended June 30, 2026. The company incurred a net loss of $0.11 per share and held $13.1 million in cash. Research and development expenses decreased to $2.1 million from $2.8 million in the prior year period. The U.S. FDA accepted the Investigational New Drug application for rexaceract, enabling Phase 2 clinical development expected in Q3 2026. Additionally, Dr. Joanne Taylor was promoted to Chief Scientific Officer and Terenzio Ignoni to Chief Operating Officer. Gain Therapeutics is a clinical-stage biotechnology company focused on discovering and developing allosteric small molecule therapies for neurodegenerative diseases.

Gain Therapeutics, Inc. announced that its current cash and cash equivalents are expected to fund operations into the second quarter of 2027. This funding includes the completion of the Phase 1b open-label extension in October 2026 and the initiation of a Phase 2 clinical study in the third quarter of 2026. Gain Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for neurological and other diseases.

Gain Therapeutics, Inc. announced on June 29, 2026, that the U.S. Food and Drug Administration (FDA) authorized its Investigational New Drug application for GT-02287. This authorization allows the company to initiate Phase 2 clinical development of GT-02287 for Parkinson's disease in the United States, Australia, and Europe. The company anticipates the initiation of the Phase 2a study of oral GT-02287 in participants with early Parkinson's disease during the third quarter of 2026. Gain Therapeutics, Inc. is a biotechnology company focused on the development of therapeutic candidates for neurological and neurological-related diseases.